On June 14, Eurosurveillance published new information on the characteristics of the German outbreak strain of E.coli and how these microbiological findings have been shared in real time by public health microbiology experts to disseminate best laboratory practice for case detection and public health investigations across Europe and beyond.
A double-blind, placebo-controlled, dose-escalation, phase 1 study was performed in 60 healthy subjects between 18 and 49 years of age. The two-dose regimen induced the development of neutralizing antibodies in high percentages of the subjects (from 88% to 100% of subjects depending on antigen content)”.